Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nintedanib + pegylated liposomal doxorubicin + carboplatin (Boehringer Ingelheim)
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of nintedanib (BIBF 1120), a triple angiokinase inhibitor, administered in conjunction with the chemotherapy agents pegylated liposomal doxorubicin (PLD) and carboplatin (CBDCA). Nintedanib is a small molecule tyrosine kinase inhibitor that targets the vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-3), and platelet-derived growth factor receptors (PDGFR alpha and beta), which are essential for tumor angiogenesis and maintenance of the tumor microenvironment. Carboplatin is a platinum-based alkylating agent that induces DNA cross-linking, while pegylated liposomal doxorubicin is an anthracycline that inhibits topoisomerase II and intercalates into DNA. This specific regimen was developed by Boehringer Ingelheim and investigated in Phase I clinical trials for the treatment of patients with platinum-sensitive relapsed advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer to determine the safety and tolerability of adding nintedanib to standard-of-care chemotherapy.
- Other names
- BIBF 1120 + PLD + carboplatinnintedanib + PLD + carboplatinnintedanib + pegylated liposomal doxorubicin + carboplatin
02
Targets
DNATOP2A (DNA topoisomerase II)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on nintedanib + pegylated liposomal doxorubicin + carboplatin (Boehringer Ingelheim).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nintedanib + pegylated liposomal doxorubicin + carboplatin (Boehringer Ingelheim).